Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Topics
  4. Market Status
  5. Rd

R&D

Thumbnail
March 17, 2023

Bad vibes continue for Merck

Thumbnail
March 13, 2023

Calliditas sets the bar for its kidney disease rivals

Article image
Vantage logo
March 07, 2023

ACC 2023 – the market tries to take Medtronic’s pulse

Being first does not always mean a clear win.

Article image
Vantage logo
March 07, 2023

Investors await details on Protagonist’s oral interleukin win

Article image
Vantage logo
March 07, 2023

Merck leads the new cholesterol-lowering push

Article image
Vantage logo
March 06, 2023

ACC 2023 – Merck’s oral cholesterol lowerer shows mid-stage promise

The oral PCSK9 project MK-0616 meets its targets in phase 2, which could be bad news for Novartis.

Article image
Vantage logo
March 06, 2023

ACC 2023 – Merck reaches for the stars

The Stellar trial of sotatercept lives up to its name, but the asset did not come cheap.

Article image
Vantage logo
March 06, 2023

Achondroplasia win propels Bridgebio

Article image
Vantage logo
March 03, 2023

Spotlight – What's next in Nash

The next few months will see some important mid-stage Nash results, from Viking, 89Bio, Northsea and others.

Article image
Vantage logo
March 02, 2023

CVRx awaits a regulatory verdict

Article image
Vantage logo
March 01, 2023

Altimmune aims to build Momentum in obesity

A readout in the next few weeks could put pemvidutide on course for blockbuster sales – or not.

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 17, 2023

PD(L)anner – February 2023

February 09, 2023

Biopharma and Medtech Review 2022

View more...

Editor's Picks

Vantage logo
March 13, 2023

Silicon Valley Bank: biopharma’s latest crisis

Vantage logo
March 13, 2023

Pfizer rescues biotech

Vantage logo
February 28, 2023

Why Pfizer (and others) will be interested in Seagen

Vantage logo
March 04, 2023

ACC 2023 – Esperion’s outcomes win looks lacklustre

Vantage logo
March 06, 2023

T-cell receptor behemoths consolidate? Not quite

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up